Evidence map›Paper›PMID 33392151›Full record

ArticleFrontiers in chemistry2020

Ola El Atab, Rabih Darwiche, Nathanyal J Truax, Roger Schneiter, Kenneth G Hull, Daniel Romo, Oluwatoyin A Asojo

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Frontiers in chemistry · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Ola El AtabDivision of Biochemistry, Department of Biology, University of Fribourg, Fribourg, Switzerland.
Rabih DarwicheDivision of Biochemistry, Department of Biology, University of Fribourg, Fribourg, Switzerland.
Nathanyal J TruaxDepartment of Chemistry and Biochemistry & The CPRIT Synthesis and Drug-Lead Discovery Laboratory, Baylor University, Waco, TX, United States.
Roger SchneiterDivision of Biochemistry, Department of Biology, University of Fribourg, Fribourg, Switzerland.
Kenneth G HullDepartment of Chemistry and Biochemistry & The CPRIT Synthesis and Drug-Lead Discovery Laboratory, Baylor University, Waco, TX, United States.
Daniel RomoDepartment of Chemistry and Biochemistry & The CPRIT Synthesis and Drug-Lead Discovery Laboratory, Baylor University, Waco, TX, United States.
Oluwatoyin A AsojoDepartment of Chemistry and Biochemistry, Hampton University, Hampton, VA, United States.
Baylor University · USUniversity of Fribourg · CHBaylor College of Medicine · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

During their infective stages, hookworms release excretory-secretory (E-S) products, small molecules, and proteins to help evade and suppress the host's immune system. Small molecules found in E-S products of mammalian hookworms include nematode derived metabolites like ascarosides, which are composed of the sugar ascarylose linked to a fatty acid side chain. The most abundant proteins found in hookworm E-S products are members of the protein family known as

Indexed as

CAP [cysteine-rich secretory protein (CRISP)/antigen 5/pathogenesis related-1 (PR-1)]lipid bindingsperm coating protein (SCP)TAPs [testis specific proteins (Tpx)/antigen 5 (Ag5)/pathogenesis related-1 (PR-1)/Sc7]venom allergen-like (VAL)

Identifiers

PMID33392151
PMCPMC7773830
OpenAlexW3121104696

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.